Trevena, Inc. (TRVN) Downgraded to Equal Weight at Barclays PLC

Trevena, Inc. (NASDAQ:TRVN) was downgraded by analysts at Barclays PLC from an “overweight” rating to an “equal weight” rating in a research report issued to clients and investors on Monday, Marketbeat reports. They presently have a $2.50 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $15.00. Barclays PLC’s price target would indicate a potential upside of 14.16% from the stock’s previous close.

A number of other research firms also recently issued reports on TRVN. Zacks Investment Research downgraded Trevena from a “buy” rating to a “hold” rating in a research note on Friday, August 25th. Cowen and Company reiterated a “buy” rating and set a $10.00 price target on shares of Trevena in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 price target on Trevena and gave the company a “buy” rating in a research note on Thursday. Finally, HC Wainwright cut their price target on Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $9.67.

Trevena (NASDAQ:TRVN) traded down 6.39% on Monday, hitting $2.05. The stock had a trading volume of 506,884 shares. The stock’s market capitalization is $122.38 million. Trevena has a 52 week low of $1.84 and a 52 week high of $8.00. The company has a 50-day moving average price of $2.47 and a 200-day moving average price of $2.72.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35). Equities research analysts anticipate that Trevena will post ($1.40) earnings per share for the current fiscal year.

WARNING: “Trevena, Inc. (TRVN) Downgraded to Equal Weight at Barclays PLC” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/16/barclays-plc-downgrades-trevena-inc-trvn-to-equal-weight.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its stake in shares of Trevena by 40.4% in the 1st quarter. Bank of New York Mellon Corp now owns 231,553 shares of the biopharmaceutical company’s stock worth $851,000 after buying an additional 66,577 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Trevena by 12.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 59,522 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 6,402 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Trevena by 38.4% in the 1st quarter. Wells Fargo & Company MN now owns 222,349 shares of the biopharmaceutical company’s stock worth $817,000 after buying an additional 61,650 shares during the last quarter. Palo Alto Investors LLC purchased a new position in shares of Trevena in the 1st quarter worth approximately $1,253,000. Finally, Highbridge Capital Management LLC purchased a new position in shares of Trev

A number of other research firms also recently issued reports on TRVN. Zacks Investment Research downgraded Trevena from a “buy” rating to a “hold” rating in a research note on Friday, August 25th. Cowen and Company reiterated a “buy” rating and set a $10.00 price target on shares of Trevena in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 price target on Trevena and gave the company a “buy” rating in a research note on Thursday. Finally, HC Wainwright cut their price target on Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $9.67.

Trevena (NASDAQ:TRVN) traded down 6.39% on Monday, hitting $2.05. The stock had a trading volume of 506,884 shares. The stock’s market capitalization is $122.38 million. Trevena has a 52 week low of $1.84 and a 52 week high of $8.00. The company has a 50-day moving average price of $2.47 and a 200-day moving average price of $2.72.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35). Equities research analysts anticipate that Trevena will post ($1.40) earnings per share for the current fiscal year.

WARNING: “Trevena, Inc. (TRVN) Downgraded to Equal Weight at Barclays PLC” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/16/barclays-plc-downgrades-trevena-inc-trvn-to-equal-weight.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its stake in shares of Trevena by 40.4% in the 1st quarter. Bank of New York Mellon Corp now owns 231,553 shares of the biopharmaceutical company’s stock worth $851,000 after buying an additional 66,577 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Trevena by 12.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 59,522 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 6,402 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Trevena by 38.4% in the 1st quarter. Wells Fargo & Company MN now owns 222,349 shares of the biopharmaceutical company’s stock worth $817,000 after buying an additional 61,650 shares during the last quarter. Palo Alto Investors LLC purchased a new position in shares of Trevena in the 1st quarter worth approximately $1,253,000. Finally, Highbridge Capital Management LLC purchased a new position in shares of Trevena in the 1st quarter worth approximately $440,000. Hedge funds and other institutional investors own 60.09% of the company’s stock.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply